Lonza Group Ag Change in Accounts Receivable 2012-2024 | LZAGY
Lonza Group Ag annual/quarterly change in accounts receivable history and growth rate from 2012 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Lonza Group Ag change in accounts receivable for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag annual change in accounts receivable for 2024 was $-0.123B, a 214.66% increase from 2023.
- Lonza Group Ag annual change in accounts receivable for 2023 was $-0.039B, a 85.24% decline from 2022.
- Lonza Group Ag annual change in accounts receivable for 2022 was $-0.264B, a 17.34% decline from 2021.
| Lonza Group Ag Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2024 | $-123 |
| 2023 | $-39 |
| 2022 | $-264 |
| 2021 | $-319 |
| 2020 | $-178 |
| 2019 | $-107 |
| 2017 | $-46 |
| 2016 | $-61 |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $50.052B | $7.468B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.506B | 27.03 |
| Boston Scientific (BSX) | United States | $157.140B | 37.47 |
| Stryker (SYK) | United States | $149.815B | 30.50 |
| EssilorLuxottica (ESLOY) | France | $148.753B | 0.00 |
| Medtronic (MDT) | Ireland | $119.490B | 16.86 |
| Haleon (HLN) | United Kingdom | $44.480B | 25.41 |
| ResMed (RMD) | United States | $42.323B | 30.27 |
| Agilent Technologies (A) | United States | $33.835B | 22.06 |
| GE HealthCare Technologies (GEHC) | United States | $33.726B | 15.85 |
| Terumo (TRUMY) | Japan | $27.731B | 32.86 |
| Koninklijke Philips (PHG) | Netherlands | $26.731B | 17.68 |
| Insulet (PODD) | United States | $23.441B | 78.54 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.941B | 13.33 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.385B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.798B | 28.64 |
| Lantheus Holdings (LNTH) | United States | $3.817B | 10.32 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.443B | 24.09 |
| Perrigo (PRGO) | Ireland | $3.255B | 8.13 |
| Prestige Consumer Healthcare (PBH) | United States | $3.201B | 14.20 |
| ICU Medical (ICUI) | United States | $3.045B | 20.73 |
| Haemonetics (HAE) | United States | $2.623B | 11.71 |
| LeMaitre Vascular (LMAT) | United States | $2.189B | 46.95 |
| QuidelOrtho (QDEL) | United States | $1.789B | 11.26 |
| Curaleaf Holdings (CURLF) | Canada | $1.750B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.687B | 72.46 |
| AdaptHealth (AHCO) | United States | $1.262B | 17.94 |
| Phibro Animal Health (PAHC) | United States | $1.262B | 16.14 |
| Acuren (TIC) | United States | $1.220B | 0.00 |
| Neogen (NEOG) | United States | $1.210B | 19.21 |
| BioLife Solutions (BLFS) | United States | $1.196B | 2496.00 |
| Tilray Brands (TLRY) | Canada | $1.167B | 0.00 |
| Valneva SE (VALN) | France | $0.979B | 0.00 |
| InMode (INMD) | Israel | $0.897B | 8.30 |
| Kestra Medical Technologies (KMTS) | United States | $0.852B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.626B | 0.00 |
| SNDL (SNDL) | Canada | $0.581B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.557B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.535B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.61 |
| Surmodics (SRDX) | United States | $0.528B | 0.00 |
| Evolus (EOLS) | United States | $0.468B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.466B | 16.04 |
| CeriBell (CBLL) | United States | $0.425B | 0.00 |
| Owens & Minor (OMI) | United States | $0.412B | 3.66 |
| Sanuwave Health (SNWV) | United States | $0.338B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.328B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.303B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.290B | 0.00 |
| Omeros (OMER) | United States | $0.285B | 0.00 |
| Brainsway (BWAY) | Israel | $0.279B | 56.81 |
| Sanara MedTech (SMTI) | United States | $0.274B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.266B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 20.18 |
| High Tide (HITI) | Canada | $0.250B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Quanterix (QTRX) | United States | $0.228B | 0.00 |
| Cerus (CERS) | United States | $0.222B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.212B | 0.00 |
| Organigram Global (OGI) | Canada | $0.201B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.185B | 15.47 |
| FitLife Brands (FTLF) | United States | $0.157B | 19.34 |
| Biote (BTMD) | United States | $0.147B | 4.87 |
| Jushi Holdings (JUSHF) | United States | $0.125B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.098B | 0.00 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.10 |
| Jin Medical (ZJYL) | China | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Safety Shot (SHOT) | United States | $0.070B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 31.80 |
| Veru (VERU) | United States | $0.052B | 0.00 |
| Zynex (ZYXI) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 34.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.21 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.031B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |